Gianluigi Condorelli

Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

ErbB2 is essential in the prevention of dilated cardiomyopathy.

Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice.

p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) modulates co-operation between myocyte enhancer factor 2A (MEF2A) and thyroid hormone receptor-retinoid X receptor.

TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor.

Expansion of specific alphabeta+ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with Coxsackievirus B infection.

Cardiomyocytes.

c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases.

Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt.

A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure.

AKT participates in endothelial dysfunction in hypertension.

Regulation of cell size and contractile function by AKT in cardiomyocytes.

Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells.

Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs.

Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer.

Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT.

Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes.

Stem cells for cardiac repair: state of the art.

Stem cells for cardiomyocyte regeneration: state of the art.

Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine.

Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals.

Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina.

Sources of cardiomyocytes for stem cell therapy: an update.

Effects of Akt on cardiac myocytes: location counts.

Human embryonic stem cell-derived cardiomyocytes: inducing strategies.

MicroRNA-133 controls cardiac hypertrophy.

Aerobic interval training enhances cardiomyocyte contractility and Ca2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban.

Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.

Human stem cells for heart failure treatment ready for prime time?

Physiological myocardial hypertrophy: how and why?

Emerging role of microRNAs in cardiovascular biology.

State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy.

MicroRNAs control gene expression: importance for cardiac development and pathophysiology.

Myocardial sarcoplasmic reticulum Ca2+ ATPase function is increased by aerobic interval training.

Carbon monoxide levels experienced by heavy smokers impair aerobic capacity and cardiac contractility and induce pathological hypertrophy.

Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment.

MicroRNA and cardiac pathologies.

MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis.

On the road to the definition of the cardiac miRNome in human disease states.

Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.

RNA silencing: small RNA-mediated posttranscriptional regulation of mRNA and the implications for heart electropathophysiology.

Role of microRNAs in haemopoiesis, heart hypertrophy and cancer.

Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability.

Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study.

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.

MicroRNAs and cardiac pathology.

Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy.

Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17.

MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.

Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions.

MicroRNAs in cardiovascular biology and heart disease.

Correlations between progression of coronary artery disease and circulating endothelial progenitor cells.

microRNAs in heart disease: putative novel therapeutic targets?

Fatty acid percentage in erythrocyte membranes of atrial flutter/fibrillation patients and controls.

Epigenetics in heart failure.

MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro.

Immersion before dry simulated dive reduces cardiomyocyte function and increases mortality after decompression.

MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.

Reliable resequencing of the human dystrophin locus by universal long polymerase chain reaction and massive pyrosequencing.

Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia.

Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy.

microRNAs in hypertrophy and heart failure.

IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.

[Cardiac stem cell therapy for the treatment of chronic stable angina refractory to conventional therapy. State of the art and current clinical experience of the San Raffaele Hospital of Milan, Italy].

Association study on long-living individuals from Southern Italy identifies rs10491334 in the CAMKIV gene that regulates survival proteins.

MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension.

ATP6V0A1 polymorphism and microRNA-637: A pathogenetic role for microRNAs in essential hypertension at last?

MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo.

Arterial remodeling and atherosclerosis: miRNAs involvement.

MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism.

Endothelial-to-mesenchymal transition and microRNA-21: the game is on again.

Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome.

The might of microRNA in mitochondria.

Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications.

[Continuity of care in heart failure: pilot study of the Tuscany region].

SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway.

CaMK4 Gene Deletion Induces Hypertension.

The circulating level of FABP3 is an indirect biomarker of microRNA-1.

Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias.

Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes.

Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.

Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy.

Circulating microRNAs and aerobic fitness--the HUNT-Study.

HEXIM1: a new player in myocardial hypertrophy?

Epigenetics: a new mechanism of regulation of heart failure?